Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, explained what testing needs to be done to identify the best treatment for patients with lung cancer.
Erin Gillaspie, MD, MPH, FACS, of Vanderbilt University Medical Center (VUMC), explained what testing must be done to identify the best treatment for lung cancer patients, noting that not every patient benefits from the same treatments. Gillaspie is a faculty member of VUMC’s Department of Thoracic Surgery and an assistant professor of thoracic surgery.
She also presented at The American Journal of Managed Care®’s Institute for Value-Based Medicine® held in Nashville, Tennessee, on August 17, 2023.
Transcript
What testing is needed to identify the best patients for certain treatments?
This is actually adding a layer of complexity to how we think about taking care of these patients now. One of the old adages we like to say all the time is "tissue is the issue," but I think I mean that more than ever right now. Because now when we're thinking about making a new lung cancer diagnosis, not only do we want to know the histology—so we want a diagnosis, we want a histology—but we also want the opportunity to do things like PD-L1 (programmed cell death ligand 1) testing, molecular testing, because immunotherapy is not the right answer for everybody. We have other molecular alterations, targetable mutations, that have dedicated therapies for them.
I think about, in particular, a treatment like osimertinib for our patients who are eGFR (epidermal growth factor receptor) positive. There are 2 primary mutations that we use osimertinib for—that's the L858R mutation and the Exon 19 deletion. We already know that that's very, very efficacious in the adjuvant setting based on the ADAURA trial. We hardly ever have disease-free survival and overall survival curves like we did in that trial. In fact, the trial was stopped early because there was such a benefit in that treatment arm.
The NeoADAURA trial is actually ongoing to help establish the efficacy of that treatment in the neoadjuvant space. One of the things that's sort of unique about some of these mutations is some of them tend to be very immunologically cooled. So, what do I mean by that? Well, immunotherapy doesn't work particularly well for them.
One of the really common mutations that I think about for that is the Exon 19 deletion. If we're not testing for that ahead of time, if we don't know that ahead of time, and then we're putting this patient on immunotherapy, not only are we giving them potential risks without benefit, but we're also potentially affecting their ability to get the therapy that's really going to give them the best outcome, which is the osimertinib.
It's really important that we do 2 different things. One, we have to get enough tissue to make sure that we understand the right treatment regimens for that patient. If that's not something that we can get ahead of time with just a biopsy, that's where all of us are starting to say, “Okay, so maybe that's a patient we don't think about neoadjuvant therapy for; we get a good resection on them, and then we give them an adjuvant to make sure that we're getting them the right therapy.”
The other piece to this is making sure we get the testing in a timely fashion. To that end, working within our teams, working with our pathology colleagues to say, “Okay, we need to get this testing back as fast as possible. So ,as soon as you have that new lung cancer diagnosis, we need to get that PD-L1 testing, we need to get the molecular testing sent off.”
Most places aren't lucky enough to be able to do that in house, and it takes a few weeks to get it back. The more that we can automate that, the more that we can get those tests sent off very quickly, the better we can deliver care in a really timely fashion to our patients.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More